Company intelligence / Profile preview

Fuji Pharma Co., Ltd.

Chiyoda-ku, Tokyo-to, Japanfujipharma.jp ↗

Ownership: Public · 4554
Employees: ~1658
Development stage: Commercial

Overview

Fuji Pharma has a strong commercial presence in Japan with a focus on women’s healthcare and acute medical care. The company has launched both generic and new drugs—including biosimilars—and maintains partnerships for pipeline expansion. It reported net sales of JPY 15 billion in 2023 with continued growth in operating profit[3]. Recent clinical launches include biosimilars such as Filgrastim BS and the scheduled launch of additional products developed with Alvotech[3][6].

Therapeutic areas: OtherOncologyWomen's Health
Modalities: Small moleculesbiosimilars
Industry: Biotech

Partnerships

Alvotech group (biosimilars development/distribution in Japan)Lotus Pharmaceutical Co., Ltd. (capital/business alliance)

Beyond the preview

Go deeper on Fuji Pharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuji Pharma Co., Ltd..

Explore the full profile